Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the management of this previously untreatable neoplasm i...
Main Authors: | Mukul Vij, Susama Patra, Mohamed Rela |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
Series: | Indian Journal of Pathology and Microbiology |
Subjects: | |
Online Access: | http://www.ijpmonline.org/article.asp?issn=0377-4929;year=2013;volume=56;issue=3;spage=291;epage=293;aulast=Vij |
Similar Items
-
Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
by: Ruth Gauden, et al.
Published: (2011-04-01) -
Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
by: Chaoyong Shen, et al.
Published: (2014-11-01) -
Postoperative Cure for Metastatic Gastrointestinal Stromal Tumor
by: Eun Hyea Park, et al.
Published: (2018-12-01) -
Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
by: Min Kyu Kang, et al.
Published: (2019-05-01) -
Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
by: Shen H, et al.
Published: (2019-12-01)